Condition: Pancreatic Cancer · Pancreatic Neoplasms · Sponsor: Cosomil, Inc.
This nationwide, multicenter, prospective, single-arm interventional feasibility study evaluates the Enzeavour Pancreatic Cancer assay in routine health checkups and cancer screening in Japan. Approximately 10,000 asymptomatic adults will be enrolled. Participants with an Enzeavour Score above 0.369 will undergo diagnostic work-up as clinically indicated. The primary outcome is pancreatic cancer detection rate within 12 months after the index blood draw, and the secondary outcome is positive predictive value.
This description comes directly from the study's public registry record.
Yu Kagami, Ph.D. · +81-3-6823-2260 · f-study@cosomil.com
Always discuss trial participation with your own doctor first.
| Aichi Medical University Hospital | Nagakute, Aichi-ken, Japan | Recruiting |
| Nagoya University Hospital | Nagoya, Aichi-ken, Japan | Recruiting |
| Hiroshima University Hospital | Hiroshima, Hiroshima, Japan | Recruiting |
| JA Onomichi General Hospital | Onomichi, Hiroshima, Japan | Recruiting |
| Obihiro Kosei Hospital | Obihiro, Hokkaido, Japan | Recruiting |
| Keijinkai Maruyama Clinic | Sapporo, Hokkaido, Japan | Recruiting |
| Teine Keijinkai Hospital | Sapporo, Hokkaido, Japan | Recruiting |
| Hotel Okura Kobe Clinic | Kobe, Hyōgo, Japan | Recruiting |
| Kobe University Hospital | Kobe, Hyōgo, Japan | Recruiting |
| Ibaraki Medical Center | Mito, Ibaraki, Japan | Recruiting |
| Mito Kyodo General Hospital | Mito, Ibaraki, Japan | Recruiting |
| Kagawa University Hospital | Kita-gun Miki-cho, Kagawa-ken, Japan | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07605819